Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma

Ilmarinen, Pinja; Juboori, Hind; Tuomisto, Leena E.; Niemelä, Onni; Sintonen, Harri; Kankaanranta, Hannu

doi:10.1038/s41598-019-52361-9

Cited by 40 publications

(41 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…52,53 In addition, long-term improvements in general health-related quality of life have been observed in patients with controlled vs partially controlled and uncontrolled asthma. 54 It would be of interest to investigate whether improved asthma control decreases the use of treatments, such as antianxiety medications, antidepressants, antimicrobial agents for respiratory infections, and therapies targeting upper airway disease. Nevertheless, as the follow-up period of this study was only 12 months in duration, it may have been too short to evaluate whether mepolizumab treatment reduced medication usage.…”

Section: Discussionmentioning

confidence: 99%

Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities

Casale

Molfino

Silver

et al. 2021

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Background: Patients with severe asthma frequently have associated comorbidities, which can compound existing symptoms, complicating asthma management. Objective: To describe the real-world effectiveness of mepolizumab in patients with severe asthma stratified by common overlapping comorbidities. Methods: This was a retrospective analysis of patients with asthma from the MarketScan Commercial and Medicare Supplemental Database initiating mepolizumab treatment (index date). Eligible patients had more than or equal to 1 claim (excluding claims for diagnostic tests) with a diagnosis code for more than or equal to 1 of 7 comorbidities (atopic disease, nasal polyps, chronic sinusitis, obesity, respiratory infections, chronic obstructive pulmonary disease, and depression/anxiety) during the 12-month preindex baseline period; these were used to stratify patients into 7 nonmutually exclusive subgroups. Outcomes included asthma exacerbations and exacerbation-related health care resource utilization during the 12-month baseline and follow-up periods. Each patient acted as their own control. Results: Of the 639 patients included, the most common comorbidities were atopic diseases (73.2%), respiratory infections (55.6%), and chronic sinusitis (45.1%). Across all 7 comorbidity subgroups, there were significant (P < .05) reductions of 38% to 55% and 57% to 83% in exacerbations and exacerbations requiring hospitalization, respectively, during the follow-up vs baseline period, except for exacerbations requiring hospitalization in the nasal polyp subgroup, owing to the small subgroup sample size. During the follow-up vs baseline periods, mean number of oral corticosteroids claims was significantly (P < .001) reduced by 29% to 38%; 39% to 47% of patients achieved greater than or equal to 50% oral corticosteroids dose reduction. Significant reductions in exacerbationrelated health care resource utilization were also observed. Conclusion: Mepolizumab treatment provided real-world clinical benefits in patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities

Casale

Molfino

Silver

et al. 2021

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

show abstract

“…It was hypothesized that patients with exacerbations would have higher scores on the total scale and subscales night's rest, feelings/emotions, physical limitation, relations and work, and asthma complaints (26). Furthermore, patients with uncontrolled asthma were hypothesized to score worse on the total scale and subscales night's rest, feelings/emotions, physical limitations, relations and work, sexuality, and asthma complaints (27,28).…”

Section: Construct Validity For People With Asthmamentioning

confidence: 99%

Hitting The Bullseye: The Psychometric Properties of the Assessment of Burden of Chronic Conditions (ABCC)-Scale in The Netherlands

Claessens

Boudewijns

Keijsers

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Chronic conditions impose a major impact on quality of life and on healthcare. The Assessment of Burden of Chronic Conditions (ABCC-)tool was developed to improve experienced quality of care and quality of life by facilitating shared decision-making and self-management. It assesses the experienced burden of one or multiple conditions, and visualises and integrates the burden in daily care. However, its scale’s validity and reliability are yet unknown. The aim of this study is to evaluate whether the ABCC-scale is valid and reliable in people with Chronic Obstructive Pulmonary Disease (COPD), asthma, or Type 2 Diabetes Mellitus (T2DM). Methods The Saint George Respiratory Questionnaire (SGRQ), the Standardized Asthma Quality of Life Questionnaire (AQLQ-S), and the Audit of Diabetes Dependent Quality of Life Questionnaire (ADDQoL19) were compared to the ABCC-scale to assess convergent validity. Convergent validity was assumed when at least 75% of the postulated correlations were higher than 0.7, or between 0.3 and 0.7 for single-item subscales. To measure known-group validity, participants were categorized according to exacerbation status, depression, asthma control, insulin dependence, complications and obesity. The ABCC-scale was deemed internally consistency upon a Cronbach’s alpha ≥ 0.90 for the total scale, and ≥ 0.70 for subscales. Test-retest reliability was evaluated at a two-week interval. Results A total of 65, 62, and 60 people with COPD, asthma, T2DM respectively were included. The ABCC-scale correlated, in accordance with hypotheses, with the SGRQ (75%), AQLQ-S (100%), and ADDQoL19 (75%). Differentiation of known-groups based on the ABCC-scale was possible for all specified groups. The total score and subscores of the ABCC-scale were internally consistent with a Cronbach’s alpha of 0.90, 0.92, and 0.91 for the total score for people with COPD, asthma, and T2DM respectively. The ABCC-scale had a good test-retest reliability with an Intraclass Correlation Coefficient of 0.95, 0.93, and 0.95 for people with COPD, asthma and T2DM respectively. Conclusions The ABCC-scale is a valid and reliable questionnaire that can be used within the ABCC-tool for people with COPD, asthma or T2DM. Future research should indicate whether this also applies to people with multimorbidity, and what the effects and experiences are upon clinical use.

show abstract

“…In addition to respiratory problems, poorly controlled asthma has been shown to reduce the general health-related quality of life and affect several aspects of human life such as mobility, sleeping, everyday activities, mental function, discomfort, depression, distress, vitality and sexual activity 39 . Poor asthma control causes symptoms affecting daily activities, well-being and quality of sleep patterns of patients, all having a negative impact on quality of life 40 .…”

Section: What Are the Consequences Of Poor Asthma Control?mentioning

confidence: 99%

Bringing asthma care into the twenty-first century

Larsson

Kankaanranta

Janson

et al. 2020

npj Prim. Care Respir. Med.

Self Cite

View full text Add to dashboard Cite

Despite access to diagnostic tests and effective therapies, asthma often remains misdiagnosed and/or poorly controlled or uncontrolled. In this review, we address the key issues of asthma diagnosis and management, recent evidence for levels of asthma control, the consequences of poor control and, in line with that, explore the potential reasons for poor asthma control and acute exacerbations. Based on recent evidence and current guidelines, we also aim to provide practical answers to the key questions of how to improve asthma management, with the best possible prevention of exacerbations, addressing the basics-adherence, inhaler misuse, obesity and smoking-and how to facilitate a new era of asthma care in the twenty-first century. We hope this review will be useful to busy primary care clinicians in their future interactions with their patients with both suspected and proven asthma.

show abstract

Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma

Cited by 40 publications

References 51 publications

Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities

Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities

Hitting The Bullseye: The Psychometric Properties of the Assessment of Burden of Chronic Conditions (ABCC)-Scale in The Netherlands

Bringing asthma care into the twenty-first century

Contact Info

Product

Resources

About